We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M Turnover 20%
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+26.96%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$271M
AUM Growth
+$110M
Cap. Flow
+$20.2M
Cap. Flow %
7.47%
Top 10 Hldgs %
43.7%
Holding
66
New
21
Increased
14
Reduced
12
Closed
4
Avg Time Held
1 year
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
1.1 years

Top Buys

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$8.07M
2
ALKS icon
Alkermes
ALKS
+$7.69M
3
AERI
Aerie Pharmaceuticals
AERI
+$5.99M
4
WVE icon
Wave Life Sciences
WVE
+$5.88M
5
TVTX icon
Travere Therapeutics
TVTX
+$4.6M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$12.4M
2
EXEL icon
Exelixis
EXEL
+$7.89M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.2M
4
LGND icon
Ligand Pharmaceuticals
LGND
+$5.95M
5
SHPG
Shire pic
SHPG
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CELG
1
DELISTED
Celgene Corp
CELG
$22.2M 8.21%
235,522
+10,000
+4% +$875K
2016 Q4
9 quarters
GILD icon
2
Gilead Sciences
GILD
$195B
$18.1M 6.68%
278,284
+65,000
+30% +$4.32M
2016 Q4
9 quarters
REGN icon
3
Regeneron Pharmaceuticals
REGN
$82B
$13M 4.8%
31,630
+300
+1% +$124K
2016 Q4
9 quarters
STML
4
DELISTED
Stemline Therapeutics, Inc.
STML
$10.2M 3.78%
796,245
+210,315
+36% +$2.38M
2017 Q1
8 quarters
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$9.95M 3.68%
73,641
– –
2016 Q4
9 quarters
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$129B
$9.4M 3.47%
51,122
-39,000
-43% -$7.2M
2016 Q4
9 quarters
NBIX icon
7
Neurocrine Biosciences
NBIX
$13.9B
$9.13M 3.37%
103,600
-22,200
-18% -$1.86M
2017 Q3
6 quarters
PTCT icon
8
PTC Therapeutics
PTCT
$5.09B
$9.05M 3.34%
+240,493
New +$8.07M
2019 Q1
0 quarters
INCY icon
9
Incyte
INCY
$23B
$8.73M 3.22%
101,500
-153,000
-60% -$12.4M
2016 Q4
9 quarters
ALKS icon
10
Alkermes
ALKS
$6.73B
$8.5M 3.14%
+233,000
New +$7.69M
2019 Q1
0 quarters
ILMN icon
11
Illumina
ILMN
$40.5B
$7.8M 2.88%
25,803
-8,738
-25% -$2.55M
2018 Q2
3 quarters
HALO icon
12
Halozyme
HALO
$13.8B
$7.66M 2.83%
475,633
+77,000
+19% +$1.25M
2016 Q4
9 quarters
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$3.4B
$7.22M 2.67%
269,000
-13,065
-5% -$305K
2018 Q3
2 quarters
AERI
14
DELISTED
Aerie Pharmaceuticals
AERI
$7.18M 2.65%
151,117
+136,117
+907% +$5.99M
2016 Q4
9 quarters
KALV icon
15
DELISTED
KalVista Pharmaceuticals
KALV
$6.06M 2.24%
213,061
-106,383
-33% -$2.31M
2016 Q4
9 quarters
ENTA icon
16
Enanta Pharmaceuticals
ENTA
$334M
$5.83M 2.15%
61,000
+18,000
+42% +$1.61M
2018 Q4
1 quarter
EXEL icon
17
Exelixis
EXEL
$15.6B
$5.79M 2.14%
243,534
-346,000
-59% -$7.89M
2016 Q4
9 quarters
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$10.8B
$5.7M 2.11%
64,284
-28,000
-30% -$2.6M
2016 Q4
9 quarters
WVE icon
19
Wave Life Sciences
WVE
$629M
$5.63M 2.08%
+145,000
New +$5.88M
2019 Q1
0 quarters
SAGE icon
20
DELISTED
Sage Therapeutics
SAGE
$5.41M 2%
33,996
+18,000
+113% +$2.61M
2016 Q4
9 quarters
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
$5.11M 1.89%
93,000
– –
2018 Q3
2 quarters
TVTX icon
22
Travere Therapeutics
TVTX
$4.98B
$4.7M 1.74%
+208,000
New +$4.6M
2019 Q1
0 quarters
AMGN icon
23
Amgen
AMGN
$235B
$4.56M 1.68%
24,000
– –
2018 Q4
1 quarter
SGEN
24
DELISTED
Seagen Inc. Common Stock
SGEN
$4.46M 1.65%
60,900
+18,400
+43% +$1.31M
2017 Q1
8 quarters
IONS icon
25
Ionis Pharmaceuticals
IONS
$7.33B
$3.88M 1.43%
47,781
+7,781
+19% +$502K
2017 Q1
8 quarters
1
2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2019 Portfolio in Review

As of Q1 2019, International Biotechnology Trust held 66 positions worth $271M, up 68% from $161M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

International Biotechnology Trust deployed $20.2M of net new capital in Q1 2019, opening 21 new positions and adding to 14 existing holdings. Its largest new stake was PTC Therapeutics: 240,493 shares worth $9.05M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Incyte, an estimated $12.4M trimmed.

  • International Biotechnology Trust's largest Q1 2019 buy was PTC Therapeutics: 240,493 shares worth $9.05M.
  • International Biotechnology Trust added most to Aerie Pharmaceuticals in Q1 2019, an estimated $5.99M increase.
  • International Biotechnology Trust's biggest Q1 2019 reduction was Incyte, cutting an estimated $12.4M.
  • International Biotechnology Trust fully exited Shire pic in Q1 2019, selling an estimated $3.42M.
  • International Biotechnology Trust's ten largest holdings make up 44% of its $271M portfolio in Q1 2019.
  • International Biotechnology Trust opened 21 new positions and closed 4 in Q1 2019.
  • International Biotechnology Trust's portfolio value rose 68% quarter-over-quarter to $271M.

Based on International Biotechnology Trust's 13F filing for Q1 2019, filed 14 May 2019.